Archive for June 2012
Viagra cardiac effects were evaluated in an open-label, uncontrolled, pilot study. The test participants received single oral doses of sildenafil up to 100 mg. The doses of the drug produced no clinically meaningful changes in the ECGs of normal males.
The eight patients taking part in this small pilot study were diagnosed with stable ischemic heart disease and underwent Swan-Ganz catheterization. They were administered a total dose of 40 mg Sildenafil by four intravenous infusions.
The study observed that the mean resting systolic and diastolic blood pressures reduced by 7% and 10% in comparison with the initial parameters in these males. Mean resting parameters for artery pressure, pulmonary artery pressure, pulmonary artery occluded pressure and cardiac output reduced by 28%, 28%, 20% and 7% respectively.
The total dosage (40 mg) of Sildenafil caused higher plasma concentrations – 2 to 5 times higher than the max plasma levels following a single oral dose of 100 mg in healthy males. Besides, the hemodynamic response to exercise endurance was preserved in the patients with cardiovascular disease.
A double-blind study involved more than 140 males with ED who were diagnosed with chronic stable exercise-induced angina not receiving regularly oral nitrates, were randomized to a single dose of placebo or Viagra 100 mg 1 hour prior to exercise testing. The main thing to evaluate was time to registering angina in the evaluable cohort. The mean times to beginning of the limiting angina were 423.6 and 403.7 seconds for sildenafil (N=70) and placebo, accordingly. These findings proved that the cardiac effect of Viagra was clinically the same as placebo.